The Leukemia & Lymphoma Society of Canada (LLS) Announces Appointments to its Board of Directors; welcomes a new board member
A wide range of influential world-class leaders make up the board of directors of LLS, a world leader in the fight against blood cancer.
RYE BROOK, NY, July 1, 2022 /PRNewswire/ — The Leukemia & Lymphoma Society (LLS) today announced appointments to the National Board of Directors, as well as a new member to the National Board of Directors. The National board of directors works alongside LLS leadership to advance the organization’s unwavering commitment to saving lives and improving the quality of life for blood cancer patients and their families.
Efficient July 1, 2022new officer appointments include: Jeff SachsPresident of the council ; Kathleen MeriwetherVice-president; Freda WangSecretary Treasurer ; Ruben MesaMD, At Large.
Also effective July 1, 2022, Jim ReddochPh.D., Executive Vice President, Investments and Chief Scientific Officer of Royalty Pharma, joins the Board of Directors.
“Volunteers are integral to the success of the LLS, and we are grateful to the distinguished volunteer leaders who serve on the LLS National Board of Directors, all focused on helping blood cancer patients and their families. families to survive and thrive,” said Louis J. De Gennaro, Ph.D., President and CEO of the LLS. “With their diverse talents and skills and their dedication to charting a bold course for the future, LLS can continue to transform the landscape of blood cancer care. We congratulate our new team of officers, welcome our new board member and look forward to the impact we will have together.”
“As a leukemia survivor and a long-time LLS volunteer and donor, I have witnessed the direct impact of LLS on the lives of blood cancer patients and families, through unprecedented advancements in research, patient services and advocacy,” said Jeff Sachs, Chairman of the SLL Board of Directors. “I am honored to chair the Board of Directors of this organization, which has exemplary management and has recently been recognized as an innovative and impactful leader among cancer organizations, with a top-notch transition of donor funds towards effective patient-focused and mission-driven programs.”
Announcements from the LLS Board of Directors and Management:
President of the council, Jeff Sachs (Atlanta, Georgia): Jeff Sachs has retired as North American Managing Director of Jones Lang LaSalle Strategic advisory and asset management group for hotels and hospitality. Prior to joining JLL, Sachs was a founding partner of the Strategic Advisory Group, which was acquired by JLL in early 2016. Prior to forming the Strategic Advisory Group in 1998, he was the National Director of the Town Hall Advisory Practice and the southeast hotel manager. convenient for Ernst & Young. He earned a bachelor’s and master’s degree in accounting from the University of Iowa. Sachs has been a volunteer at LLS since 2005, a year after surviving a diagnosis of acute myeloid leukemia.
Vice-president, Kathleen Meriwether (Philadelphia, Pennsylvania): Kathleen Meriwether is retired from Ernst & Young, LLP, where she served as Americas Life Sciences Lead for Forensic Practice and Firm Integrity. She specializes in assisting health science companies with internal and governmental investigations, global risk and compliance assessments, and regulatory compliance analyses. Prior to joining Ernst & Young, she served as an Assistant U.S. Attorney in the U.S. Attorney’s Office for the Eastern District of Pennsylvania, specializing in healthcare fraud cases. Previously, she spent over 16 years with Bristol-Myers Squibb Company in a number of legal, regulatory and compliance roles, including Division Advisor for the Oncology and Immunology Franchise. Kathleen holds a bachelor’s degree in economics from LaSalle University and got his JD from Villanova University Law School. She is also a board member of Novartis Corporation and is a cancer survivor.
Secretary Treasurer, Freda Wang (New York, NY): Freda Wang is Managing Director of the Public Sector and Infrastructure Group at Goldman Sachs in the Investment Banking Division. Prior to joining Goldman Sachs, she was Managing Director and Head of Structured Banking Operations in the Municipal Securities Group at UBS. Wang has spent more than two decades providing investment banking services to some of the nation’s largest public sector organizations, including state and local governments, utility systems, transportation and transit agencies. and other public and quasi-public organizations. Over the course of her career, she has assisted numerous government, corporate and non-profit clients with complex financing issues related to public projects. Freda was named 2018 Woman of the Year for the Connecticut Westchester Hudson Valley Chapter of LLS. She is currently treasurer and board member of FUSE Corps, and vice chair of the board and chair of the finance committee of New York City Health & Hospitals. Freda earned a bachelor’s degree in urban studies with a concentration in economics Columbia College at Columbia University in New York City.
In general, Ruben MesaMDFACP (San Antonio, TX): Dr. Mesa is executive director of the NCI-designated Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, a National Cancer Institute-designated cancer center, where he holds the Presidential Chair of the Mays Family Foundation Distinguished University. Dr. Mesa has been a principal or co-principal investigator in over 100 clinical trials for patients with myeloid disorders and has played a leading role in various FDA approvals. He has been a National Cancer Institute (NCI) funded investigator on several projects in myeloproliferative neoplasms and is appointed to the NCI Clinical Trials Advisory Board. Dr. Mesa holds various leadership positions within the American Society of Hematology and was elected to the Board of Directors of the American Association of Cancer Institutes. Dr. Mesa completed his undergraduate training in nuclear engineering and physiology at University of Illinois and attended Mayo Medical School in Rochester, Minnesota, where he completed his residency in internal medicine and his internship in hematology and medical oncology. He then served on the Mayo Clinic faculty in hematology and later served as deputy director of the Mayo Clinic Cancer Center from 2012 to 2017.
Crew member, Jim Reddochdoctorate (New York, NY): Jim Reddoch, Ph.D. is Executive Vice President, Investments and Chief Scientific Officer at Royalty Pharma, where he has identified and analyzed new investment opportunities and biopharmaceutical partnerships for over 14 years. Prior to joining Royalty Pharma in 2008, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. He is a member of Memorial Sloan Kettering Cancer Center’s External Review Board for its Technology Development Fund. Dr. Reddoch holds a bachelor’s degree from Furman UniversityPhD in Biochemistry and Molecular Genetics from University of Alabama faculty of medicine and was a postdoctoral fellow at Yale University.
About the Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is a world leader in the fight against cancer. The mission of the LLS: To cure leukemia, lymphoma, Hodgkin’s disease and myeloma. The LLS funds vital blood cancer research worldwide, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality coordinated care. , affordable.
Founded in 1949 and based in Rye Creek, NYLLS has regional offices across United States and Canada. To learn more, visit www.LLS.org. Patients should contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
The Leukemia and Lymphoma Society
SOURCE The Leukemia & Lymphoma Society (LLS)